Reparixin

DB12614InvestigationalSmall molecule

Reparixin has been used in trials studying the treatment and prevention of Breast Cancer, Metastatic Breast Cancer, Pancreatectomy for Chronic Pancreatitis, Islet Transplantation in Diabetes Mellitus Type 1, and Pancreatic...

Mechanism: Pharmacologically active on C-X-C chemokine receptor type 1 and C-X-C chemokine receptor type 2
Curator reviewed
Formula / weight: C₁₄H₂₁NO₃S · 283.39 g/mol (avg)
Code names: DF -1681Y

Resolves to

Compound

UNIIU604E1NB3KCAS266359-83-5ChEMBLCHEMBL191413PubChem9838712

Structure

InChIKeyKQDRVXQXKZXMHP-LLVKDONJSA-NSMILESCC(C)CC1=CC=C(C=C1)[C@@H](C)C(=O)NS(C)(=O)=O

Targets

P25024CXCR1P25025CXCR2

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

14Clinical trialsPhase, status and sponsor resolved per trial

12+ReferencesStructured and connected to the statements they support

Which drugs share a target with Reparixin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account